Logo

CombiMatrix Reports $5.8 Million in Q2 Cash Payments

Jul 01, 2003

NEW YORK, July 1 - CombiMatrix generated $5.8 million in cash payments for the second quarter, the company's parent, Acacia Research, said today.

 

CombiMatrix has a semiconductor-based microarray technology, which it is marketing and using to develop siRNA compounds that target common viral diseases.

 

The Squolamie, Wash., company did not specify the source of CombiMatrix's revenues, but CombiMatrix CEO Amit Kumar did mention the company's collaboration with Roche, its strategic alliance with Toppan, and the launch of the siRNA drug discovery program, Express Track.

Breaking News
The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.